Taken together, the results presented show that inhibitors of the serine/threonine kinase CK2 may be useful either as monotherapy or even more potent in combination therapy with the tyrosine kinase inhibitor, Imatinib, for the treatment of leukemias caused by the Bcr/Abl oncogene. In the preclinical model used here, we have shown that especially the combination of the two drugs may be useful in eradicating cells that appear to linger after the initial treatment with a single drug,
Treatment of P190 Bcr/Abl lymphoblastic leukemia cells with inhibitors of the serine/threonine kinase CK2
PINNA, LORENZO;
2007
Abstract
Taken together, the results presented show that inhibitors of the serine/threonine kinase CK2 may be useful either as monotherapy or even more potent in combination therapy with the tyrosine kinase inhibitor, Imatinib, for the treatment of leukemias caused by the Bcr/Abl oncogene. In the preclinical model used here, we have shown that especially the combination of the two drugs may be useful in eradicating cells that appear to linger after the initial treatment with a single drug,
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
